✦ LIBER ✦

A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials

✍ Scribed by Mashele M. Huschka; Sumithra J. Mandrekar; Paul L. Schaefer; James R. Jett; Jeff A. Sloan

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 163 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22444

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prognostic model for advanced stage no

A prognostic model for advanced stage nonsmall cell lung cancer : Pooled analysis of North Central Cancer Treatment Group trials

✍ Sumithra J. Mandrekar; Steven E. Schild; Shauna L. Hillman; Katie L. Allen; Rand 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 2 views

## Abstract ## BACKGROUND. A pooled analysis was performed to examine the impact of pretreatment factors on overall survival (OS) and time to progression (TTP) in patients with advanced‐stage nonsmall cell lung cancer (NSCLC) and to construct a prediction equation for OS using pretreatment factors

Prognostic factors differ by tumor stage

Prognostic factors differ by tumor stage for small cell lung cancer : A pooled analysis of North Central Cancer Treatment Group trials

✍ Nathan R. Foster; Sumithra J. Mandrekar; Steven E. Schild; Garth D. Nelson; Kend 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

## Abstract ## BACKGROUND: An analysis of 14 small cell lung cancer (SCLC) trials was performed to improve the current understanding of potential prognostic factors for overall survival (OS) and progression‐free survival (PFS) in groups of patients with limited‐stage disease SCLC (LD‐SCLC) and ext

Statistical analysis of quality of life

Statistical analysis of quality of life with missing data in cancer clinical trials

✍ Andrea B. Troxel; Diane L. Fairclough; Desmond Curran; Elizabeth A. Hahn 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB 👁 2 views

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud

A phase III trial of 5-fluorouracil and

A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study

✍ Michael J. O'Connell 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 2 views

The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment

A phase II evaluation of menogaril in ci

A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the north central cancer treatment group and the mayo clinic

✍ Harry J. Long III; John A. Laurie; Harry S. Wieand; John H. Edmonson; Ralph Levi 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 2 views

Tumor response and progression-free surv

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer : Findings on the basis of North Central Cancer Treatment Group trials

✍ Nathan R. Foster; Yingwei Qi; Qian Shi; James E. Krook; John W. Kugler; James R. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views